Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine

Tyler Davis, Sherif S Farag Department of Internal Medicine, Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Acute lymphoblastic leukemia (ALL) remains a disease with poor outcomes in adults. While induction chemotherapy achieves a complete...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Davis T, Farag SS
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/4b3cc98f6a52462583d9f6b9dcc9c5a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4b3cc98f6a52462583d9f6b9dcc9c5a6
record_format dspace
spelling oai:doaj.org-article:4b3cc98f6a52462583d9f6b9dcc9c5a62021-12-02T01:19:11ZTreating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine1176-91141178-2013https://doaj.org/article/4b3cc98f6a52462583d9f6b9dcc9c5a62013-09-01T00:00:00Zhttp://www.dovepress.com/treating-relapsed-or-refractory-philadelphia-chromosome-negative-acute-a14365https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Tyler Davis, Sherif S Farag Department of Internal Medicine, Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Acute lymphoblastic leukemia (ALL) remains a disease with poor outcomes in adults. While induction chemotherapy achieves a complete remission in almost 90% of patients, the majority will relapse and die of their disease. Relapsed ALL is associated with a high reinduction mortality and chemotherapy resistance, with allogeneic hematopoietic stem cell transplantation offering the only therapy with curative potential. However, there is no efficacious and well tolerated standard regimen accepted as a “bridge” to allogeneic stem cell transplantation or as definitive treatment for patients who are not transplant candidates. Vincristine is an active drug in patients with ALL, but its dose intensity is limited by neurotoxicity, and its full potential as an anticancer drug is thus not realized. Encapsulation of vincristine into sphingomyelin and cholesterol nanoparticle liposomes facilitates dose-intensification and densification to enhanced target tissues with reduced potential for toxicity. Vincristine sulfate liposome injection (VSLI) is associated with significant responses in clinically advanced ALL, and has recently been approved by the US Food and Drug Administration for treatment of relapsed and clinically advanced Philadelphia chromosome-negative ALL. This review provides an overview of the preclinical and clinical studies leading to the approval of VSLI for the treatment of relapsed and refractory ALL, and suggests potential areas of future clinical development. Keywords: vincristine, lymphoblastic leukemia, liposomeDavis TFarag SSDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 3479-3488 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Davis T
Farag SS
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
description Tyler Davis, Sherif S Farag Department of Internal Medicine, Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Acute lymphoblastic leukemia (ALL) remains a disease with poor outcomes in adults. While induction chemotherapy achieves a complete remission in almost 90% of patients, the majority will relapse and die of their disease. Relapsed ALL is associated with a high reinduction mortality and chemotherapy resistance, with allogeneic hematopoietic stem cell transplantation offering the only therapy with curative potential. However, there is no efficacious and well tolerated standard regimen accepted as a “bridge” to allogeneic stem cell transplantation or as definitive treatment for patients who are not transplant candidates. Vincristine is an active drug in patients with ALL, but its dose intensity is limited by neurotoxicity, and its full potential as an anticancer drug is thus not realized. Encapsulation of vincristine into sphingomyelin and cholesterol nanoparticle liposomes facilitates dose-intensification and densification to enhanced target tissues with reduced potential for toxicity. Vincristine sulfate liposome injection (VSLI) is associated with significant responses in clinically advanced ALL, and has recently been approved by the US Food and Drug Administration for treatment of relapsed and clinically advanced Philadelphia chromosome-negative ALL. This review provides an overview of the preclinical and clinical studies leading to the approval of VSLI for the treatment of relapsed and refractory ALL, and suggests potential areas of future clinical development. Keywords: vincristine, lymphoblastic leukemia, liposome
format article
author Davis T
Farag SS
author_facet Davis T
Farag SS
author_sort Davis T
title Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
title_short Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
title_full Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
title_fullStr Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
title_full_unstemmed Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
title_sort treating relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/4b3cc98f6a52462583d9f6b9dcc9c5a6
work_keys_str_mv AT davist treatingrelapsedorrefractoryphiladelphiachromosomenegativeacutelymphoblasticleukemialiposomeencapsulatedvincristine
AT faragss treatingrelapsedorrefractoryphiladelphiachromosomenegativeacutelymphoblasticleukemialiposomeencapsulatedvincristine
_version_ 1718403137867350016

Ejemplares similares